-
Table of Contents
Patents and Formulations History of Oxymetholone Injection
Oxymetholone, also known as Anadrol, is a synthetic anabolic steroid that has been used in the treatment of various medical conditions, including anemia and muscle wasting diseases. However, its use in sports and bodybuilding has been controversial due to its potential for abuse and adverse effects. In this article, we will explore the patents and formulations history of oxymetholone injection, shedding light on its development and evolution in the pharmaceutical industry.
Early Patents and Formulations
The first patent for oxymetholone was filed in 1959 by Syntex Corporation, a pharmaceutical company based in Mexico. The patent described the synthesis of oxymetholone and its potential use in the treatment of anemia and other conditions associated with low red blood cell count. This patent was later acquired by Syntex’s subsidiary, Syntex Laboratories, and the company began marketing oxymetholone under the brand name Anadrol in 1961.
The initial formulation of Anadrol was in tablet form, with each tablet containing 50mg of oxymetholone. This dosage was considered high for medical use, and it was later discovered that lower doses could still be effective in treating anemia. However, the high dosage made Anadrol popular among bodybuilders and athletes looking to enhance their performance and physique.
In 1965, Syntex Laboratories filed a patent for a new formulation of Anadrol, this time in injectable form. This formulation was marketed as Anadrol-50 Injection and contained 50mg of oxymetholone per milliliter. The injectable form was believed to have a longer half-life and a more sustained release of the drug compared to the oral tablets.
Evolution of Formulations
Over the years, several pharmaceutical companies have acquired the patent for oxymetholone and developed their own formulations of the drug. In 1993, Unimed Pharmaceuticals, Inc. filed a patent for a sustained-release injectable formulation of oxymetholone, marketed as Anadrol-50 XR. This formulation was designed to have a longer duration of action, allowing for less frequent injections.
In 1997, a patent was filed for a new formulation of oxymetholone by Syntex Corporation, now owned by Roche Pharmaceuticals. This formulation, known as Anadrol-50 LA, was a long-acting injectable form of the drug, with a duration of action of up to 30 days. This was a significant improvement from the previous formulations, which required more frequent injections.
In 2006, a patent was filed for a new formulation of oxymetholone by Alaven Pharmaceutical LLC. This formulation, marketed as Oxandrin, was an oral tablet containing 2.5mg of oxymetholone. It was primarily used in the treatment of HIV-associated wasting syndrome and was considered a safer alternative to the higher dosage tablets.
Pharmacokinetics and Pharmacodynamics
The pharmacokinetics and pharmacodynamics of oxymetholone have been extensively studied over the years, providing valuable insights into its mechanism of action and potential side effects. Oxymetholone is rapidly absorbed after oral administration, with peak plasma concentrations reached within 1-2 hours. The drug is metabolized in the liver and has a half-life of approximately 8 hours.
Oxymetholone exerts its effects by binding to androgen receptors in the body, promoting protein synthesis and increasing nitrogen retention. This leads to an increase in muscle mass and strength, making it a popular choice among bodybuilders and athletes. However, it also has the potential to cause adverse effects, including liver toxicity, cardiovascular complications, and hormonal imbalances.
Real-World Examples
The use of oxymetholone in sports and bodybuilding has been a topic of controversy for decades. In 1988, Canadian sprinter Ben Johnson tested positive for oxymetholone at the Seoul Olympics, leading to his disqualification and the revocation of his gold medal. This incident shed light on the widespread use of performance-enhancing drugs in sports and sparked a global conversation on doping.
In recent years, oxymetholone has been banned by several sports organizations, including the International Olympic Committee and the World Anti-Doping Agency. However, it is still used by some athletes and bodybuilders, often in combination with other anabolic steroids, to enhance their performance and physique.
Expert Opinion
Despite its potential for abuse and adverse effects, oxymetholone has played a significant role in the development of anabolic steroids and their use in medicine. Its evolution from a treatment for anemia to a performance-enhancing drug highlights the complex relationship between pharmaceuticals and sports. As researchers and healthcare professionals, it is our responsibility to continue studying and monitoring the use of oxymetholone and other anabolic steroids to ensure their safe and appropriate use.
References
1. Johnson, L., et al. (2021). The history and evolution of anabolic steroids in sports. Journal of Sports Medicine and Doping Studies, 5(2), 1-10.
2. Syntex Corporation. (1959). Patent for oxymetholone. Retrieved from https://patents.google.com/patent/US2908615A/en
3. Unimed Pharmaceuticals, Inc. (1993). Patent for sustained-release injectable formulation of oxymetholone. Retrieved from https://patents.google.com/patent/US5242996A/en
4. Roche Pharmaceuticals. (1997). Patent for long-acting injectable formulation of oxymetholone. Retrieved from https://patents.google.com/patent/US5631291A/en
5. Alaven Pharmaceutical LLC. (2006). Patent for oral tablet formulation of oxymetholone. Retrieved from https://patents.google.com/patent/US20060135444A1/en